Published 3 days ago • loading... • Updated 3 days ago

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso, Inc. Announced the publication of its Phase III clinical trial results for ivonescimab compared to pembrolizumab in The Lancet.
The study showed that ivonescimab significantly extended progression-free survival by reducing disease progression risk by 49% compared to pembrolizumab.
The supplemental New Drug Application for ivonescimab as a first-line treatment for PD-L1 positive NSCLC is under priority review in China.
The HARMONi-2 study results were presented by Professor Zhou Caicun at the 2024 World Conference on Lung Cancer.

Insights by Ground AI

Does this summary seem wrong?

47 Articles

All

Left

Center

Right

The Conway Daily Sun

+45 Reposted by 45 other sources

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared…

3 days ago

Read Full Article

The Conway Daily Sun

+45 Reposted by 45 other sources

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

3 days ago

Read Full Article

pipelinereview

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet - Pipelinereview

HONG KONG, China I March 7, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”)is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have bee…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year